Evidence map›Paper›PMID 42886793›Full record

ArticleScience advances2026

Programmable and selective silencing of oncogenic fusion transcripts by CRISPR-Cas13b via breakpoint sequence recognition.

Wenxin Hu 胡文欣, Honglin Chen 陈竑霖, Steven He, Joshua M L Casan, Carolyn Shembrey, Sharon Li, Lauren M Brown, Andrea Zhao, Lynda Truong, Isabella Buchner and 11 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Science advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Wenxin Hu 胡文欣Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia.ORCID 0000-0002-0330-5200
Honglin Chen 陈竑霖Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia.ORCID 0009-0008-7469-7716
Steven HeChildren's Cancer Institute, Lowy Cancer Research Centre, UNSW Sydney, NSW Australia 2052.ORCID 0000-0002-3113-9588
Joshua M L CasanPeter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia.ORCID 0000-0002-4322-8561
Carolyn ShembreyPeter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia.
Sharon LiOlivia Newton-John Cancer Research Institute, Heidelberg, Melbourne, Australia.
Lauren M BrownChildren's Cancer Institute, Lowy Cancer Research Centre, UNSW Sydney, NSW Australia 2052.ORCID 0000-0002-4322-8203
Andrea ZhaoChildren's Cancer Institute, Lowy Cancer Research Centre, UNSW Sydney, NSW Australia 2052.ORCID 0000-0001-5898-096X
Lynda TruongCentre for Cancer Research, Hudson Institute of Medical Research, VIC Australia 3168.
Isabella BuchnerCentre for Cancer Research, Hudson Institute of Medical Research, VIC Australia 3168.
Dane VassiliadisPeter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia.ORCID 0000-0002-7814-4851
Timothy P HughesPrecision Cancer Medicine Theme. South Australian Health and Medical Research Institute (SAHMRI). Adelaide SA.ORCID 0000-0002-0910-3730
Deborah L WhitePrecision Cancer Medicine Theme. South Australian Health and Medical Research Institute (SAHMRI). Adelaide SA.ORCID 0000-0003-4844-333X
Catherine L CarmichaelCentre for Cancer Research, Hudson Institute of Medical Research, VIC Australia 3168.
Antoine De WeckChildren's Cancer Institute, Lowy Cancer Research Centre, UNSW Sydney, NSW Australia 2052.ORCID 0000-0003-0887-6771
Ilia VoskoboinikPeter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia.ORCID 0000-0002-6410-009X
Quentin GouilOlivia Newton-John Cancer Research Institute, Heidelberg, Melbourne, Australia.ORCID 0000-0002-5142-7886
Joseph A TrapaniPeter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia.ORCID 0000-0003-0983-1532
Paul G EkertPeter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia.ORCID 0000-0002-2976-8617
Teresa SadrasPeter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia.ORCID 0000-0001-9048-9580
Mohamed FarehPeter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia.ORCID 0000-0001-9551-8213

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Oncogenic gene fusions are key drivers of cancer, yet most remain undruggable by current therapies. Here, we establish CRISPR-

Indexed as

CRISPR-Cas SystemsFusion Proteins, bcr-ablGene SilencingOncogene Proteins, FusionCell Line, TumorDrug Resistance, NeoplasmHumansLeukemia, Myelogenous, Chronic, BCR-ABL PositiveFusion Proteins, bcr-ablOncogene Proteins, Fusion

Identifiers

PMID42886793
PMCPMC13674509

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.